Last edition
News about "blood cancer drug development"
Eli Lilly and Company to Acquire Ajax Therapeutics to Expand Blood Cancer Pipeline
Eli Lilly and Company to acquire Ajax Therapeutics, advancing its blood cancer pipeline with AJ1-11095, a Phase 1 JAK2 inhibitor targeting myelofibrosis and polycythemia vera, with potential for improved disease control.
Blood Cancer Drug Development | 28/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members